首页> 外文期刊>Molecular cytogenetics >Analysis of chromosome 22q11 copy number variations by multiplex ligation-dependent probe amplification for prenatal diagnosis of congenital heart defect
【24h】

Analysis of chromosome 22q11 copy number variations by multiplex ligation-dependent probe amplification for prenatal diagnosis of congenital heart defect

机译:多重结扎依赖性探针扩增染色体22Q11拷贝数变化对先天性心脏缺陷的产前诊断

获取原文
           

摘要

Congenital heart defects (CHD) represent one of the most common birth defects. This study aimed to evaluate the value of multiplex ligation-dependent probe amplification (MLPA) as a tool to detect the copy number variations (CNVs) of 22q11 in fetuses with CHD. A large cohort of 225 fetuses with CHD was screened by fetal echocardiography. Once common chromosome abnormalities in 30 fetuses were screened out by conventional G-banding analysis, the CNVs of chromosome 22q11 in the remaining 195 fetuses were determined by MLPA for prenatal genetic counseling. In 195 CHD fetuses with normal karyotype, 11 cases had pathological CNVs, including 22q11.2 deletion (seven cases), the deletion of 22q11 cat eye syndrome (CES) region (one case), 22q11.2 duplication (one case), 22q13.3 deletion (one case) and 17p13.3 deletion (one case). In total, our findings from MLPA screening represented 4.9?% in our cohort. Among these, three cases were inherited CNVs, and eight cases were de novo. These CNVs were further verified by single nucleotide polymorphism (SNP)-array analysis, and their chromosomal location was refined. This study indicated that MLPA could serve as an effective test for routine prenatal diagnosis of 22q11 in fetuses with CHD.
机译:先天性心脏缺陷(CHD)代表最常见的出生缺陷之一。该研究旨在评估多重连接依赖性探针扩增(MLPA)作为检测胎儿胎儿22Q11的拷贝数变化(CNV)的工具的价值。胎儿超声心动图筛选了患有CHD的大队列的225胎。一旦通过常规G发带分析筛选了30胎儿常见的染色体异常,通过MLPA用于产前遗传咨询,测定染色体22Q11中的CNV的CNV。在195年CHD胎儿具有正常核型,11例病理CNV,包括22Q11.2缺失(7例),缺失22Q11猫眼综合征(CES)区域(一例),22Q11.2重复(一例),22Q13 .3删除(一个案例)和17p13.3删除(一个案例)。总共,我们的队列中的MLPA筛查的调查结果为4.9?%。其中,三种病例是遗传性CNV,八种病例为DE Novo。通过单核苷酸多态性(SNP) - array分析进一步验证这些CNV,并精制其染色体位置。本研究表明,MLPA可以作为患有CHD胎儿22Q11的常规产前诊断的有效试验。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号